Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27072915 | 0.72 | CALM1 (0.55) | CALM1ALDH1A1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL3728814 | 0.70 | CALM1 (0.46) | CALM1HPGDALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL11330543 | 0.67 | KCNH2 (0.62) | CALM1ALDH1A1RAB9ASMN1; SMN2TDP1 | |
| Diphenylmethane SCHEMBL1303 | 0.66 | CALM1 (1.00) | CALM1HPGDALDH1A1LMNAMAOB | |
| Diphenylmethane SCHEMBL3792579 | 0.66 | CALM1 (1.00) | CALM1HPGDALDH1A1LMNAMAOB | |
| Diphenylmethane SCHEMBL4361124 | 0.66 | CALM1 (1.00) | CALM1HPGDALDH1A1LMNAMAOB | |
| Diphenylmethane SCHEMBL14763944 | 0.66 | CALM1 (1.00) | CALM1HPGDALDH1A1LMNAMAOB | |
| Diphenylmethane SCHEMBL28172316 | 0.66 | CALM1 (1.00) | CALM1HPGDALDH1A1LMNAMAOB | |
| SCHEMBL15323022 | 0.66 | CALM1 (0.61) | CALM1HPGDALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL25048215 | 0.65 | ALDH1A1 (0.43) | CALM1ALDH1A1RAB9ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2023151635-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2023-08-17 | — | — | WO | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| WO-2023030170-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | claimed |
| WO-2023284703-A1 | PROTEIN DEGRADATION COMPOUND DESIGNED ON THE BASIS OF BRUTON'S TYROSINE KINASE LIGAND AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-01-19 | — | — | WO | claimed |
| WO-2021222147-A1 | HETEROCYCLIC GCN2 MODULATORS | HIBERCELL, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-20180291036-A1 | PROCESS FOR PREPARING THIADIAZOLO-ISOINDOLE-DIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-10-11 | — | — | US | claimed |
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | claimed |
| US-6410792-B1 | OBESITY DISEASES | BAYER CORPORATION | 2002-06-25 | — | — | US | claimed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | claimed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | claimed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | claimed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | claimed |
| US-6048900-A | FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA | BAYER CORPORATION (US) | 2000-04-11 | — | — | US | claimed |
| EP-0910565-A1 | AMIDE DERIVATIVES AS SELECTIVE NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Bayer Corporation (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1998035957-A1 | AMIDE DERIVATIVES AS SELECTIVE NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BAYER CORPORATION (US) | 1998-08-20 | — | — | WO | claimed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | CALM1 383/4885GLA 2471/4885HPGD 4039/4885 |
| US-20180291036-A1 | PROCESS FOR PREPARING THIADIAZOLO-ISOINDOLE-DIONE DERIVATIVES | TDO2, DRD5, DRD4 | CALM1 3760/4885GLA 4838/4885HPGD 662/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | CALM1 1253/4885GLA 2518/4885HPGD 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.